US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioPhausia - Year end report 2001

Year end report 2001 * Sales amounted to SEK 2.071.000 (SEK 975.000 ) * Rights for RescueFlow® acquired in the Nordic countries * New approvals for RescueFlow® in Europe * Distribution agreement for RescueFlow® in Asia * Positive results from pre-clinical studies within BP 04 project * Patents for BP 04 in the USA and Australia * Saving plans are implemented * The net result for the fiscal year amounted to a loss of SEK 23.818.000 (loss SEK 24.765.000); SEK 12.744.000 (SEK 12.034.000) of which were research and development costs. Important events after the close of the period * Patents in

BioPhausia - positive results BP04

PRESSRELEASE BioPhausia - positive results BP04 Preclinical studies within project BP04 (more effective cancer treatment with cytostatics) shows proof of concept at four levels. Earlier information 1. Treatment with BP04 decreases the pressure in the tumour (basic mechanism of action). 2. Increased uptake of marker in tumour has been documented Studies recently reported show: 3. Treatment with BP04 induces increased uptake of cytostatics (in tumour tissue). 4. In a model designed to study the effects of tumour growth the results show a significant decrease of tumour growth (and a tendency

Interim report January - September 2000

Interim report January - September 2000 * Break through för RescueFlow® in Europe * Distribution agreements in France, Germany and Israel * RescueFlow® increases survival at sepsis * Promising results from RescueFlow® surgery study * BioPhausia has acquired distribution rights to Haemopressin® * BioPhausia subsidiary GlycoVisc has acquired exclusive license rights to patent * The Board has decided on a new share issue * The net result for the period amounted to a loss of SEK 17.693.000 (loss 19.280.000); SEK 8.821.000 (14.368.000) of which were research and development costs. Break through

Interim report January-September 2000

Interim report January - September 2000 * Breakthrough for RescueFlow® in Europe * Distribution agreements in France, Germany and Israel * RescueFlow® increases survival at sepsis * Positive results from RescueFlow® surgery study * BioPhausia has acquired distribution rights to Haemopressin® * BioPhausia subsidiary GlycoVisc has acquired exclusive license rights to patent * The Board has decided on a new share issue * The net result for the period amounted to a loss of SEK 17 693 000 (loss 19 280 000); SEK 8 821 000 (14 368 000) of which were research and development costs Breakthrough for

RescueFlow[R] improves survival in early sepsis

PRESS RELEASE RescueFlow® improves survival in early sepsis Results from two independent studies where RescueFlow® (7.5% sodium chloride, 6% dextran 70) has been used for septic shock, have recently been presented by two Swedish research groups. "The findings of these studies from respected research institutes are a major step forward in our program for the further development of RescueFlow® and confirm those from previous studies on RescueFlow®," says Soili Longsén, Managing Director of BioPhausia. During the European Society for Intensive Care Medicine congress in Rome, early October 2000,

Breakthrough for RescueFlow in Europe

PRESS RELEASE Breakthrough for RescueFlow ® in Europe Karolinska Hospital and South Hospital include RescueFlow in prehospital routine care. Karolinska Hospital and South Hospital in Stockholm, Sweden, have included RescueFlow in the SOPs, Standard Operating Procedures, for prehospital care. This is a prerequisite for routine care and broader usage of RescueFlow in ambulances and helicopters. The process was initiated almost one year ago by the trauma care groups at the two hospitals in cooperation with the management of BioPhausia and leading specialists. The trauma committees at

BioPhausia an innovative Swedish pharmaceutical company introduces RescueFlow in Europe

BioPhausia - an innovative Swedish pharmaceutical company introduces RescueFlow® in Europe BioPhausia will be participating in the following conferences and meetings. Welcome to meet us at the congress site. Pressinformation will be available at the site. European Society of Intensive Care Medicine 1-4 October 13 th Annual Congress ROME ITALY 1-4 October 2000 Palazzo dei Congressi Please meet as at the Booth No : 16bis (Ground Floor ) BioContact Quebec 99 October 6-8 2000 A biopharmaceutical Partnership FORUM, Quebec Canada Company presentation during the meeting. Contacts can be made at

BioPhausia - introduces RescueFlow in Germany

BioPhausia - an innovative Swedish Pharmaceutical company introduces RescueFlow® in Germany BioPhausia is an innovative Swedish pharmaceutical company listed on the Swedish Stock Exchange. BioPhausia is a research and development company with core competence and scientific research within the area of microcirculation, macro- molecules and biopolymers. BioPhausia is focusing on research and development within these core competence areas, as well as using its European Distributor Network and global marketing & sales experience for product introductions targeting hospital specialists in Europe.

Interim report January - June 2000

Interim report January - June 2000 * Distribution agreement signed for RescueFlow® in France. * New sales office in Germany. * Soili Longsén appointed new Managing Director. * Claes Thulin new Chairman of the Board * Annual General Meeting authorised the Board to decide on new share issue. * The net result for the period amounted to a loss of SEK 12.074.000 (loss: 15.091.000), of which SEK 5.734.000 (10.211.000) were research and development expenses. Events after the period January-June 2000 Biophausia signs distribution agreement in Germany BioPhausia has signed a distribution agreement

Interim report January - March 2000

Interim report January - March 2000 * Distribution agreement signed for RescueFlow®. * Directed placement to AB Traction. * Skandia converts its Series B shares to Series A shares. * Soili Longsén appointed new Managing Director. * Annual General Meeting authorized the Board to decide on a new share issue. * The net result for the period amounted to a loss of SEK 5.939.000 (loss: 9.285.000), SEK 2.499.000 (6.570.000) of which were research and development costs. Distribution agreement for RescueFlow® BioPhausia has during the period focused its operations on discussions and negotiations

Preliminary report on 1999 operations

Preliminary report on 1999 operations * RescueFlow® approved for sale in eight EU countries * Activities proceeding as planned for new application to the FDA for approval of RescueFlow® * Studies covering use of RescueFlow® in surgery under way. * Krillase® project sold to Convergence AB * Issue of convertible debenture loan totaling SEK 24,992,261 implemented * New organization implemented * Net result for the fiscal year amounted to a loss of SEK 27,776,000 (loss: 47,777,000), of which research and development costs amounted to SEK 18,728,000 (34,913,000). RescueFlow® RescueFlow® was

Interim Report Nine months ended September 30, 1999

Interim Report Nine months ended September 30, 1999 *A convertible debenture loan totalling SEK 24,992,261 underwritten by AB Traction (publ) will be issued. *Rescue Flow® wins final approval for sale in eight EU countries; negotiations continue with several presumptive distributors and licensees *Preliminary agreement reached concerning transfer of Krillase® project. *Net result for the period amounted to a loss of SEK19,514,000 (loss35,738,000)of which research and development costs amounted to SEK 14,368,000 (26,053,000). *New market-oriented organization now under development.

Interim Report January - June 1999

Interim Report January - June 1999 *RescueFlow® was launched in Sweden as first country. *Seven EU countries have announced they will approve RescueFlow® for marketing. A business plan for the international launch of RescueFlow® has been prepared. *The Krill project under BioPhausia's management has been terminated, but work completed to date is being documented. *The net result for the period amounted to a loss of SEK 15,091,000 (loss: 25,308,000), of which research and development costs amounted to SEK 10,211,000 (18,312,000). *The Board of Directors and management is adapting the company'

New Chairman of the Board

New Chairman of the Board Focus on RescueFlow® Johannes Norrby, Chairman of the BioPhausia Board, today announced his resignation. The Board intends to call an extraordinary General Meeting to be held after the summer. Until this meeting the Board has elected Bertil Larsson as Chairman. RescueFlow® is a small volume resuscitation solution, approved for marketing in Sweden, and to be approved in another seven EU countries. The Board has decided to focus on the value inherent in RescueFlow® and the preclinical projects, and is working on the bridging financing necessary to secure their best

BioPhausia halts development costs

Biophausia halts development costs At a meeting held on June 14, 1999, the Board of Biophausia discussed the company's future strategy. In an analysis of the present situation, the value of Krillase for wound cleansing is deemed to be negligible based on current negotiations. RescueFlow is expected to generate revenue in the future, but this requires intermediate financing to gain sufficient time for negotiations and to start sales. Most of the personnel will be released as soon as possible using the funds now available. The Board's work will also continue to focus on protecting the

Interim report January - March 1999

Interim report January - March 1999 * A further seven EU countries have announced they will approve RescueFlow® for marketing. * The Annual General Meeting voted unanimously to authorize the Board of Directors to decide on a possible new share issue. * The Annual General Meeting elected Ulf Holmström and Gösta Jonsson as new Board members. * The net result for the period amounted to a loss of SEK 9,285,000 (loss: 16,035,000). * Research and development costs amounted to SEK 6,570,000 (10,745,000). Krillase® In mid-April, a smaller study concerning Krillase® was launched. The purpose of the

RescueFlow will be approved in further EU countries

RescueFlow® will be approved in further EU countries BioPhausia today announces that RescueFlow®, based on the approval of the Swedish Medical Products Agency, will get marketing authorisations in Great Britain, Germany, France, The Netherlands, Denmark, Finland and Austria. The formal national registrations are expected within 1-3 months. It is later possible to apply in additional EU countries in a second wave of the registration procedure. Erika Kjellberg Eriksson, President, BioPhausia: " The approval of RescueFlow® for marketing in these significant countries is a great success. Our

Decisions at the Annual General Meeting

Decisions at the Annual General Meeting The BioPhausia Annual General Meeting on April 26 1999 authorized the Board of Directors of BioPhausia AB (publ) to decide on a new issue of Series A and/or Series B shares, whereby the issue may be effected without regard to shareholders´ preferential rights. The maximum number of shares thus issued will be 10,000,000. The Annual General Meeting decided on changes in the Articles of Association of the Company with regard to the activities of the Company, as well as revisions required by changes in the Companies Act. The Annual General Meeting decided

Proposed candidates for BioPhausia Board

Proposed candidates for BioPhausia Board In consultation with the existing Board of Directors, a group consisting of Per-Johan Björnstedt, portfolio manager in Skandia AB, and Stellan Lind, President of BioPhausia through February 1, 1999, has prepared the following proposed list of Board candidates for presentation to shareholders at the Company's Annual General Meeting on April 26. The proposal is supported by Skandia, Förenade Liv and a number of the employees. Ulf Holmström, Vice President, Group Treasury, SEB, new election. Gösta Jonsson, President of Astra Arcus AB, new election.

Notice of 1999 Annual General Meeting

BioPhausia AB (publ) Notice of 1999 Annual General Meeting Shareholders in BioPhausia AB (publ) are hereby called to the Annual General Meeting, to be held on April 26, 1999, at 2:00 p.m., in the Company's premises at Rubanksgatan 3 in Knivsta, Sweden. Notification: Shareholders who desire to participate in the Meeting must:be recorded in the share register maintained by the Swedish Securities Register Center (Värdepapperscentralen, VPC AB) not later than Friday, April 16, 1999 have notified the Company of their desire to participate not later than 4:00 p.m. on April 21, 1999, by mail

The Board proposes share issue

[REMOVED GRAPHICS] PRESS RELEASE The BioPhausia Board proposes the Annual General Meeting to authorize the Board to decide on a new share issue The Board of Directors of BioPhausia AB (publ) proposes to the Annual General Meeting on April 26 1999 to authorize the Board to decide on a new issue of Series A and/or Series B shares, whereby the issue may be effected without regard to shareholders´ preferential rights. The shares thus issued may result in a total increase in share capital of not more than SEK 25,000,000 (10,000,000 shares at a par value of SEK 2.50 each). Johannes Norrby,

Preliminary report on 1998 operations

Preliminary report on 1998 operations Following the results of the Phase III studies of krill enzymes for wound debridement, it is clear that the project has a value that is considerably lower than previously assumed. @ O perating expenses in 1999 are less than SEK 2 M per month. ® Following the Swedish Medical Products Agency's approval of RescueFlow , an agreement was signed with Pharmalink to market the product in the Nordic countries. A patent application for using hyaluronidase to treat traumatic swelling has been approved. @ R esearch and development costs amounted to SEK 34.9 M (36.2)

1997 Year End Report

1997 Year End Report -The Board of Directors has decided, subject to the approval of the Annual General Meeting to be held on March 12, 1998, to implement a new share issue, with preferential rights for shareholders, in an amount of MSEK 57. Work is proceeding according to plan regarding the listing of the company on the Stockholm Stock Exchange "O List." -During the year, the company changed its name from Medisan Pharmaceuticals AB to BioPhausia AB. -The dextran operation, with the exception of the RescueFlow® and Perfadex® development projects, was sold. Payment received for the divested

There are no items matching the current filter
There are no more items matching the current filter
Back to top